• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Mauna Kea touts data from Cellvizio lung transplant study

Mauna Kea touts data from Cellvizio lung transplant study

May 25, 2017 By Fink Densford

Mauna Kea

Mauna Kea (ENT:MKEA) this week presented data from a study examining the use of its Cellvizio platform in assessing acute lung rejection following transplant.

Data from the study was presented at the 2017 American Thoracic Society’s International Conference.

The Cellvizio device is designed for use in a variety of surgical procedures, providing real time visualization at the microscopic level, Mauna Kea said.

Results from follow-up exams of 24 lung transplant patients were used in the study, with CLE video-imaging obtained prior to tissue sampling, Mauna Kea said. Endomicroscopy video-images from the Cellvizio were blindly reviewed by 4 pulmonologists independently and then with a consensus meeting.

Reproducibility was assessed by calculating IntraClass Correlation Coefficient and Fleiss Kappa before and after the consensus meeting, with scores of 0.77 and 0.39 respectively pre-consensus, and 0.96 and 0.77 post-consensus.

Study results indicated that perivascular cellularity observed with Cellvizio “provides a feasible and reproducible criterion to assess acute lung rejection in vivo,” according to a press release.

“Probe-based Confocal Laser Endomicroscopy represents a potential new tool to provide a less-invasive diagnosis of acute lung rejection in lung transplant recipients requiring trans-bronchial biopsies. The results from our study suggest that pCLE could potentially save patients from unnecessary invasive biopsies. We look forward to further studying this endomicroscopy application in order to better enhance the treatment continuum for lung transplant patients,” Dr. Cesar Keller of Jacksonville, Fla.’s Mayo Clinic said in prepared remarks.

“This study provides further evidence of the broad potential of the Cellvizio platform to improve diagnostic and treatment outcomes. We thank Dr. Keller and his colleagues for conducting this unique study sponsored by Mauna Kea Technologies and demonstrating that with proper training, the procedure is effective and reproducible. We are optimistic that Cellvizio will increasingly be used in a variety of applications that can benefit from its unique ability to provide real-time diagnostic information at the cellular level. Moreover, image interpretation automation with artificial intelligence will contribute to the performance and adoption of Cellvizio in this and other applications,” CEO & founder Sacha Loiseau said in a press release.

In April, Mauna Kea released data from the National French Registry on Cellvizio procedures, touting strong performance of its confocal laser endomicroscopy in diagnosing major gastrointestinal diseases when compared to historical findings.

The results were presented at the Meeting on Hepato-Gastroenterology and Digestive Oncology in Paris.

Filed Under: Clinical Trials, Imaging Tagged With: Mauna Kea Technologies

More recent news

  • Former Intuitive sales leader joins surgical robot maker Virtual Incision as CEO
  • Smith+Nephew to open first orthopedic ambulatory surgery center in the UK
  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy